Frontlight ResearchEarly access
Active, not recruitingPhase 1/2
Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects
Key facts
- Who runs it
- Ikaria Bioscience Pty Ltd
- Where
- Dilworth, Houston, Pleasant View, Tamarac, Versailles, and Webster, United StatesSee the 6 sitesAlso in 1 other country, 4 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1/2
- People taking part
- 108 people, planned
- Started
- 30 Sept 2024
- Ended
- 26 Aug 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- RN0361
- Record updated
- 30 December 2025
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (25)Hide the full registry criteria
Who can take part
- Willing to provide written informed consent before any study-specific procedures
- Comply with the study requirements and restrictions as listed in the Informed Consent Form and the protocol
- Fasting serum triglyceride levels > 80 mg/dL and fasting LDL-C ≥70 mg/dL at screening
- Female participants must either be nonchildbearing or, if of childbearing potential, not pregnant, not breastfeeding, and using effective contraception. Male participants must use condoms and ensure their partners use contraception if they are of childbearing potential
- Participants must avoid sperm or egg donation during the study
- Willing to provide written informed consent before any study-specific procedures
- Comply with the study requirements and restrictions as listed in the Informed Consent Form and the protocol
- Fasting serum triglyceride levels ≥ 300 mg/dL at screening
- Female participants must either be nonchildbearing or, if of childbearing potential, not pregnant, not breastfeeding, and using effective contraception. Male participants must use condoms and ensure their partners use contraception if they are of childbearing potential
Who cannot take part
- Recent vaccination with live vaccines, except for influenza, or plans to receive such during the study
- Positive tests for alcohol or drugs of abuse at screening
- Active pancreatitis within 12 weeks prior to Day 1
- Alcohol or drugs abuse
- History or presence of any serious or uncontrolled disease
- History of multiple drug allergies or allergic reactions to specific components used in the study; Phase II:
- History or presence of any serious or uncontrolled disease
- Uncontrolled hypertension (sitting blood pressure) >160/100 mm Hg
- Uncontrolled diabetes
- Symptomatic heart failure (NYHA II-IV)
- Positive serologic test of HBV, HCV, or HIV
- History of multiple drug allergies or history of allergic reaction to an oligonucleotide or GalNAc
- History of intolerance to SC injection or relevant abdominal scarring (surgical, burns, etc)
- History of malignancy within the last 2 years prior to the date of consent; Note: Additional inclusion/exclusion ceiteria may apply, per protocol
- clinically significant health concerns
Other criteria
- Phase I:
Where in United States
Also in 1 other country, 4 sites
- Axis Clinicals USADilworth, United States
- Synergy Groups MedicalHouston, United States
- Ogden Clinic, Mountain View / AvacarePleasant View, United States
- TBC Research LLC,Tamarac, United States
- Versailles Family Medicine / AvacareVersailles, United States
- TranquilWebster, United States
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of single doses of RN0361 in Adult healthy subjects and Adult Hypertriglyceridemic Subjects.
The 2 groups in the trial
- RN0361Treatment being tested
subcutaneous injections
- PlaceboPlacebo, for comparison
calculated volume to match active treatment
Treatment: RN0361
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1, Randomized, Placebo-controlled, Single Ascending Dose and Phase 2 Randomized, Placebo Controlled, Parallel-Group, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic Effects, and Immunogenicity of RN0361 in Adult Healthy Subjects and Hypertriglyceridemic Subjects
- Record updated
- 30 December 2025